Product Information

TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB is a generic product labeled by Actavis Pharma, Inc., priced at $0.0954 per EA under NDC 00591042405. Its NADAC has been published 677 times since Nov 28, 2013.

FDA first approved this application on Sep 23, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB

Triamterene and Hydrochlorothiazide
$0.0954per EA

Strength

25; 37.5 mg/1; mg/1

NDC

00591042405

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA073449

FDA Approved

9/23/1993

TE Code

AB

On Market Since

9/23/1993

Pharmacological Classes

Decreased Renal K+ Excretion
Increased Diuresis
Increased Diuresis
Potassium-sparing Diuretic
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB has been published 677 times since Nov 28, 2013, and over the history we have for it it has declined 43.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0954 per EA
All-time high$0.1760 (Feb 12, 2014)
All-time low$0.0721 (Nov 20, 2024)
52-week high$0.0983
52-week low$0.0930
Median price$0.1065
Average price$0.1158
Largest weekly change-29.0% (Nov 20, 2024)
Weeks tracked677
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

-1.6%

3M

-2.7%

6M

-0.2%

1Y

+4.3%

3Y

+4.5%

5Y

-7.9%

All

-43.2%

Generic Alternatives

The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB, manufactured by Actavis Pharma, Inc., is $0.0954 per EA (NDC 00591042405), effective Nov 11, 2026.

How has the price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB changed over time?

Over the history we have for it, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB has declined 43.2%. It has been tracked across 677 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?

Since Nov 28, 2013, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB has ranged from a low of $0.0721 (Nov 20, 2024) to a high of $0.1760 (Feb 12, 2014), with a median of $0.1065 per EA.

Are there cheaper alternatives to TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?

5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB in a comparable dosage form, but none are currently priced below it.

Who manufactures TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?

TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB (NDC 00591042405) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.